Assessment of the CALLY Index, a Novel Immunonutrivite Marker, in Perioperatively Treated Gastric Cancer Patients

Objective: This study aimed to investigate the prognostic significance of the C-reactive protein-albumin-lymphocyte (CALLY) index in patients with early-stage gastric cancer and compare it with other immune markers, such as systemic immune-inflammation index (SII), neutrophil lymphocyte ratio (NLR), and prognostic nutritional index (PNI). Methods: We retrospectively analyzed patients with early-stage gastric cancer who received adjuvant or perioperative chemotherapy. Laboratory results were obtained from the preoperative period. The CALLY index was calculated as follows: serum albumin level (g/dL) x absolute lymphocyte counts (109/L) / CRP (mg/dL) x104. Results: A total of 74 patients were included in the study. The median relapse-free survival (RFS) was 13.0 (95 %CI: 7.7-18.2) months in the low CALLY index group and 38.2 (95% CI:18.4-57.8) months in the high CALLY index group (p